Skip to content
value.today
Atara Biotherapeutics, Inc. logo

Atara Biotherapeutics, Inc.

ATRA
$96 Mmarket cap on Oct 23, 2026+108.9% since Jan 2024
Compare
World rank
#18,848
Revenue
$121 M
For year ending December-2025
Net income
$33 M
27.1% margin
SEC filing
Employees
578
As on 2021
value.today research

Atara Biotherapeutics, Inc. in brief

Atara Biotherapeutics, Inc. is a listed company in the Biotechnology industry, based in Thousand Oaks, California, USA. It was founded in 2012. Its market value was $96 M on 23 October 2026, which makes it the 18,848th largest listed company in the world and the 3,528th largest in the USA on this site. In the year to December 2025 it had sales of $121 M and a net profit of $33 M, about 27 cents of profit for every dollar of sales. It employs about 578 people and AnhCo Nguyen is its chief executive. Its shares trade under the symbol ATRA (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics is a off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. It is estimated that the annual revenue is currently $36M per year and has 450 Employees as on 2019. The headquarters is in USA.

Atara Biotherapeutics, Inc. timeline

4 events, 2012–2024
  1. 2012
  2. 🏁
    · approximate
    Founded
  3. 2014
  4. 🔔
    · approximate
    Initial public offering on Nasdaq
  5. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  6. 2024
  7. 💰
    Record revenue of $129 million
    FY2024, the highest of the 4 years on record.

Events of Atara Biotherapeutics, Inc. from Wikidata, the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$440 M$880 M$1.3 B$1.8 B2020202120222023202420252026

World rank over time

▼ down 10,769 places since 2020
2020-01-01: #8128#8,12820202021-01-01: #6129#6,12920212022-01-07: #7703#7,70320222022-12-25: #16070#16,07020222023-07-30: #17990#17,99020232024-01-05: #25336#25,33620242026-03-08: #11338#11,33820262026-08-01: #18023#18,02320262026-10-14: #19017#19,01720262026-10-23: #18897#18,8972026

Rank in USA: #2,027 (Jan 2020) · #1,801 (Jan 2021) · #2,245 (Jan 2022) · #3,303 (Dec 2022) · #3,597 (Jul 2023) · #4,110 (Jan 2024) · #2,205 (Mar 2026) · #3,536 (Aug 2026) · #3,516 (Oct 2026) · #3,532 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
2.9×
Price / sales
0.8×
Price / book
—
Free cash flow yield
-53.0%
Net margin
27.1%
Operating margin
29.7%
Return on equity
—
Liabilities / assets
290.2%
Revenue growth
-6.3%
R&D / revenue
31.0%
Revenue per employee
$209 K
Profit per employee
$57 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-231M—FY18Fiscal year ending Dec 2019: revenue —, net income $-291M—FY19Fiscal year ending Dec 2020: revenue —, net income $-307M—FY20Fiscal year ending Dec 2021: revenue —, net income $-340M—FY21Fiscal year ending Dec 2022: revenue $64M, net income $-228M$64MFY22Fiscal year ending Dec 2023: revenue $9M, net income $-276M$9MFY23Fiscal year ending Dec 2024: revenue $129M, net income $-85M$129MFY24Fiscal year ending Dec 2025: revenue $121M, net income $33M$121MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$121M-6.3%$36M$33M27.1%
Dec 2024$129M+1404.6%$-83M$-85M-66.2%
Dec 2023$9M-86.5%$-276M$-276M-3222.1%
Dec 2022$64M—$-281M$-228M-359.1%
Dec 2021——$-340M$-340M—
Dec 2020——$-309M$-307M—
Dec 2019——$-296M$-291M—
Dec 2018——$-237M$-231M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-51M$0M$-51M$2.57—
Dec 2024$-69M$0M$-69M$-11.41—
Dec 2023$-193M$1M$-194M$-65.19—
Dec 2022$-270M$4M$-275M$-2.24—
Dec 2021$-221M$11M$-231M$-3.63—
Dec 2020$-181M$5M$-185M$-4.15—
Dec 2019$-236M$6M$-241M$-5.67—
Dec 2018$-180M$36M$-216M$-5.27—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $33M, net income $-13M$33MDec ’24Three months to Mar 2025: revenue $98M, net income $38M$98MMar ’25Three months to Jun 2025: revenue $18M, net income $2M$18MJun ’25Three months to Sep 2025: revenue $3M, net income $-4M$3MSep ’25Three months to Dec 2025 (from the annual report): revenue $2M, net income $-3M$2MDec ’25Three months to Mar 2026: revenue $1M, net income $-4M$1MMar ’26Three months to Jun 2026: revenue $1M, net income $-5M$1MJun ’26Three months to Sep 2026: revenue $1M, net income $-2M$1MSep ’26

Latest quarter to Sep 2026: revenue $1M (-64.6% on a year earlier), net income $-2M. Lighter bars: fourth quarters worked out from the annual report.

SEC filings

Official filings of Atara Biotherapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$121 M
Operating income
$36 M
Net income
$33 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$20 M
Total liabilities
$59 M
Total equity
$-39 M

As of December-2025

Top 35 institutional investors in Atara Biotherapeutics, Inc.#

As of Sep 30, 2026
35 institutions held 4.6 M shares (about 45.1% of the shares outstanding) on Sep 30, 2026. The ten largest hold 43.3%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Atara Biotherapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1EcoR1 Capital, LLC1,552,0000 (0.00%)15.23%$13 MNov 16, 2026
2Adage Capital Partners GP, L.L.C.850,0000 (0.00%)8.34%$7 MNov 16, 2026
3Point72 Asset Management, L.P.677,696-10,022 (-1.46%)6.65%$6 MNov 16, 2026
4Redmile Group, LLC636,852+195,151 (+44.18%)6.25%$5 MNov 16, 2026
5Vanguard Capital Management LLC247,0470 (0.00%)2.42%$2 MNov 13, 2026
6Mackenzie Financial Corp176,758-56,491 (-24.22%)1.73%$2 MNov 2, 2026
7BlackRock, Inc.85,302+847 (+1.00%)0.84%$1 MNov 13, 2026
8Geode Capital Management, LLC80,950+5,822 (+7.75%)0.79%$1 MNov 6, 2026
9Vanguard Fiduciary Trust Co50,703+7,667 (+17.82%)0.50%$0 MNov 13, 2026
10Staley Capital Advisers Inc50,0000 (0.00%)0.49%$0 MNov 6, 2026
11Citadel Advisors LLC43,079+32,920 (+324.05%)0.42%$0 MNov 16, 2026
12State Street Corp26,4530 (0.00%)0.26%$0 MNov 12, 2026
13UBS Group AG20,756+16,777 (+421.64%)0.20%$0 MNov 10, 2026
14Northern Trust Corp16,705+114 (+0.69%)0.16%$0 MNov 16, 2026
15FMR LLC16,278+40 (+0.25%)0.16%$0 MNov 10, 2026
16Bridgeway Capital Management, LLC13,760-240 (-1.71%)0.14%$0 MNov 16, 2026
17Empowered Funds, LLC13,760New0.14%$0 MNov 13, 2026
18Acadian Asset Management LLC11,538-27,307 (-70.30%)0.11%$0 MNov 9, 2026
19Morgan Stanley9,176-2 (-0.02%)0.09%$0 MNov 13, 2026
20Royal Bank Of Canada8,751+4,008 (+84.50%)0.09%$0 MNov 16, 2026
21Employees Retirement System of Texas5,154New0.05%$0 MNov 10, 2026
22Vanguard Global Advisers, LLC4,654+3,198 (+219.64%)0.05%$0 MNov 13, 2026
23SBI Securities Co., Ltd.1,4040 (0.00%)0.01%$0 MOct 22, 2026
24Jones Financial Companies Lllp303-500 (-62.27%)0.00%$0 MNov 13, 2026
25Caitong International Asset Management Co., Ltd266-45 (-14.47%)0.00%$0 MOct 29, 2026
Show all 35: investors 26 to 35
Institutional investors 26 to 35 in Atara Biotherapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Wells Fargo & Company/mn2510 (0.00%)0.00%$0 MNov 16, 2026
27Jpmorgan Chase & Co222+6 (+2.78%)0.00%$0 MNov 12, 2026
28Tower Research Capital LLC (TRC)221New0.00%$0 MNov 16, 2026
29Barclays PLC214-90 (-29.61%)0.00%$0 MNov 6, 2026
30BNP Paribas Financial Markets460 (0.00%)0.00%$0 MNov 12, 2026
31KERR FINANCIAL PLANNING Corp240 (0.00%)0.00%$0 MNov 17, 2026
32Osaic Holdings, Inc.100 (0.00%)0.00%$0 MNov 12, 2026
33Rockefeller Capital Management L.P.80 (0.00%)0.00%$0 MNov 13, 2026
34Citigroup Inc1-96 (-98.97%)0.00%$0 MNov 4, 2026
35IFP Advisors, Inc1New0.00%$0 MOct 16, 2026

Mutual funds holding Atara Biotherapeutics, Inc.#

15 funds hold shares worth $4 M (about 3.4% of the company). Since their previous reports 7 added shares and 3 sold, buying $0 M net.
Mutual funds holding Atara Biotherapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.158,646$2 M1.6%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.82,758$1 M0.81%<0.01%+47%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC29,408$0 M0.29%<0.01%−1.6%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors17,227$0 M0.17%0.01%+65%Jun 30, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC16,238$0 M0.16%0.03%no changeJun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC14,000$0 M0.14%0.11%no changeJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC10,479$0 M0.10%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC8,665$0 M0.09%<0.01%+13%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC4,612$0 M0.05%<0.01%+72%May 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.2,844$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.2,799$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.1,643$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC1,147$0 M0.01%<0.01%+48%Jun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC210$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP135$0 M<0.01%<0.01%no changeJul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 15 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Atara Biotherapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$5.7 M
2 purchases, 2 insiders
Sold, 12 months
$3.8 M
14 sales, 4 insiders
Net, 12 months
$1.9 M
open market only
Insiders on file
44
since
$4.7 M-$3.2 M$0Nov 2023: bought $195 K (4 trades), sold $25 K (6 trades)Nov 23Mar 2024: bought $0 (0 trades), sold $40 K (6 trades)May 2024: bought $0 (0 trades), sold $131 K (5 trades)MayAug 2024: bought $0 (0 trades), sold $53 K (12 trades)Nov 2024: bought $0 (0 trades), sold $45 K (3 trades)NovMar 2025: bought $0 (0 trades), sold $39 K (3 trades)May 2025: bought $0 (0 trades), sold $37 K (2 trades)MayJul 2025: bought $186 K (1 trades), sold $0 (0 trades)Aug 2025: bought $670 K (1 trades), sold $55 K (6 trades)AugNov 2025: bought $0 (0 trades), sold $62 K (5 trades)Jan 2026: bought $0 (0 trades), sold $489 K (1 trades)Jan 26Mar 2026: bought $0 (0 trades), sold $26 K (8 trades)May 2026: bought $4.7 M (1 trades), sold $3.2 M (3 trades)MayAug 2026: bought $0 (0 trades), sold $41 K (1 trades)Sep 2026: bought $1000 K (1 trades), sold $0 (0 trades)SepNov 2026: bought $0 (0 trades), sold $39 K (1 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Atara Biotherapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed AnhCo NguyenPresident and CEO, DirectorSell-6,094$6.460$39 K126,681Form 4
filed Brian N. CherryDirectorBuy+104,166$9.600$1000 K166,486Form 4
filed AnhCo NguyenPresident and CEO, DirectorSell-5,062$8.080$41 K132,775Form 4
filed Redmile Group, LLCDirectorOption exerciseindirect+195,211——636,912Form 4
filed Redmile Group, LLCDirectorShares withheld for taxindirect-60——636,852Form 4
filed Brian N. CherryDirectorGrant or award+24,000——62,320Form 4
filed Matthew K. FustDirectorGrant or award+12,000——30,188Form 4
filed Gregory Austin CiongoliDirector, 10% ownerGrant or award+12,000——12,000Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Atara Biotherapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
296,651
4.0% of shares · 13.43 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-1.3 reverse split

Trading halts

  • 2026-05-07 19:30 UTC, code LUDP, resumed 19:40 UTC
  • 2026-05-07 16:14 UTC, code LUDP, resumed 16:19 UTC
  • 2026-05-07 14:50 UTC, code LUDP, resumed 14:55 UTC
  • 2025-01-16 13:25 UTC, code T3, resumed 14:00 UTC

Fails to deliver

  • : 114 shares at $9.43
  • : 2,836 shares at $9.31
  • : 1,707 shares at $9.38
  • : 216 shares at $9.37
  • : 283 shares at $9.40

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Atara Biotherapeutics, Inc. scorecard#

Passes 11 of the 18 checks that could be worked out: strongest in growth (4 of 5), weakest in financial health (1 of 3). Fiscal year 2025; market cap of Oct 23, 2026.

  • Valuation3 of 5
    • ✓P/E below its peers' median2.9×P/E 2.9× against Biotechnology's median of 17.5×.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • ✓Price to sales below its peers' median0.8×Price to sales 0.8× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-53.0%Free cash flow is -53.0% of the market value.
    • ✓Earnings yield above the 10-year Treasury yield34.0%Earnings yield 34.0% against the 10-year Treasury's 5.15% on 2026-11-13.
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth4 of 5
    • ✗Revenue grew in the newest year-6.3%Revenue down 6.3% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years23.9%23.9% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median23.9%23.9% a year against Biotechnology's median of 12.9% (181 companies).
    • ✓Earnings per share grew in the newest year2.57 vs -11.41Diluted EPS 2.57 in fiscal 2025 against -11.41 the year before (report's currency).
    • ✓Net income higher than five years earlier$33 M$33 M in fiscal 2025 against -$307 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability3 of 4
    • ✓Profitable in the newest year$33 MNet income $33 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • ✓Operating margin above its peers' median29.7%29.7% against Biotechnology's median of -60.5% (243 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier29.7%29.7% in fiscal 2025 against -441.3% in 2022.
  • Financial health1 of 3
    • ✗Short-term assets cover short-term liabilities0.8×Current ratio 0.82 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✓Operating income covers interest five times9.5×Operating income 9.5 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year69.8%Diluted shares up 69.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Atara Biotherapeutics, Inc.'s statements, beside the median of Biotechnology.

Atara Biotherapeutics, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin29.7%-60.5%
Net margin27.1%-68.9%
Revenue growth, 3 years a year23.9%12.9%
Revenue growth-6.3%15.8%
Free cash flow margin-42.2%-61.5%

4of 7on the Piotroski tests of financial strength

  • Revenue fell 6.3% against the year before.
  • Free cash flow was negative: -$51 million.
  • Only -156% of net income arrived as cash from operations.
  • The share count rose 69.8% in the year.

Atara Biotherapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Atara Biotherapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue1211298.664——————
Research and development371512252732822452161678157
General and administrative26405172796480704025
Operating expenses———34436130929623712281
Total costs and expenses85212285344——————
Operating income36−83−276−281−340−309−296−237−122−81
Interest expense and finance costs3.84.65.30.4——————
Other non-operating income (expense)−0.00.5−0.2−0.7r0.42.44.76.42.02.2
Income before tax33−85−276−228−340−307−291−231−120−79
Income tax0.0−0.00.00.00.00.00.0−0.0−0.00.0
Net income including minority interests33−85−276−228−340−307−291−231−119−79
Net income attributable to shareholders33−85−276−228−340−307−291−231−119−79
Earnings per share, basic2.61-11.41-65.19r-2.24-3.63-4.15-5.67-5.27-4.00-2.75
Earnings per share, diluted2.57-11.41-65.19r-2.24-3.63-4.15-5.67-5.27-4.00-2.75
Shares, weighted average (basic)137.54.2r1029474————
Shares, weighted average (diluted)137.54.2r102947451443029
Balance sheet
Cash and cash equivalents8.525269310620074617948
Short-term investments0172615026530018524987208
Receivables1.31.534401.01.30———
Inventory0119.71.60—————
Other current assets2.5106.210122114125.94.7
Current assets1265102295385523273321172261
Property, plant and equipment0.11.33.96.354515469443.3
Right-of-use (leased) assets7.14055682612140——
Total assets20109166376468588343392218264
Accounts payable0.14.43.76.9177.18.03.7152.8
Current liabilities1513514279106833740289.7
Lease liabilities (non-current)9.33046582613140——
Non-current liabilities———————13120.5
Total liabilities5920626525018912652534010
Retained earnings−2,022−2,055−1,969−1,693−1,465−1,125−818−527−297−177
Shareholders' equity−39−9799r127280462291339r178254
Total liabilities and equity20109166376468588343392218264
Shares outstanding7.35.94.3r96928357463129r
Cash-flow statement
Depreciation and amortization2.15.14.85.79.38.37.13.71.00.4
Share-based compensation9.8274554545152342317
Cash from operating activities−51−69−193−270−221−181−236−180−88−60
Capital expenditure0−0.2−1.2−4.2−11−4.5−5.7−36−20−3.0
Cash from investing activities188.612420322−12160−196100r84
Shares issued1.59.32.12299694848190
Cash from financing activities16592.053104428189358200.5
Change in cash————————3124
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Atara Biotherapeutics, Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.

Atara Biotherapeutics, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters2 offices—
🇮🇪 Ireland1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Atara Biotherapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.1 M
Dr. Nguyen
Other top executives, average
$1.0 M
the CEO earned 1× this
$100 invested is now
$22
Atara Biotherapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Dr. Nguyen$1.1 M$1.1 M$1.0 M$22
2024AnhCo Nguyen$1.7 M$1.3 M$872 K$3
2023Dr. Touchon served$4.4 M$557 K$2.3 M$3

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Atara Biotherapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Restructuring 4 · Directors and officers 5 · Material agreement 3 · Unregistered share sale 1 · Shareholder vote 2 · Results announced 10

Atara Biotherapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Directors and officers8-K
Directors and officersShareholder vote8-K
Delisting notice8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Restructuring8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Directors and officersResults announced8-K
Restructuring8-K
Material agreement8-K
Directors and officers8-K
Results announced8-K
Restructuring8-K
Restructuring8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Lobbying by Atara Biotherapeutics, Inc.#

$30 K spent on lobbying the US Congress and federal agencies in 2025.

Lobbying, 2025
$30 K
#1,415 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
$20 K

Lobbying firms hired in 2025

King & Spalding LLP $30 K

Atara Biotherapeutics, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$20 K—2
2025$30 K—2
2024$120 K—4
2023$240 K—4
2022$240 K—4
2021$220 K—4

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Atara Biotherapeutics, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Atara Biotherapeutics, Inc.#

2 labor condition applications certified in fiscal 2025 for 2 positions, at a median wage of $97 K a year.

Certified, FY2025
2
#1,588 among companies on value.today
Worker positions
2
Median wage offered
$97 K
a year, full-time
Applications filed
2
Atara Biotherapeutics, Inc.: most frequent H-1B job titles in fiscal 2025
Job titlePositionsMedian wage offered
Associate ScientistMicrobiologists1$73 K
Sr. Data Engineer, Process MonitoringIndustrial Engineers1$120 K

Where: Thousand Oaks, CA 1 · Frisco, TX 1

Atara Biotherapeutics, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202522$97 K2
FY202422$87 K2
FY20231313$101 K13
FY202288$115 K8
FY20211414$90 K14
FY202088$110 K8

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Atara Biotherapeutics, Inc.

Layoffs at Atara Biotherapeutics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
365
2022–2025
Latest
—
2025-10-06
Atara Biotherapeutics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2025··31·········31
202444···········44
2023··········73·73
2022140······77····217
Atara Biotherapeutics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
29% of workforceRestructuring planSEC 8-K“(the “Company”) announced a reduction in its workforce that will impact approximately 29% of its current employees, retaining approximately 15 employees essential to executing on t…”Filing
30% of workforceRestructuring planSEC 8-K“(the “Company”) announced a reduction in its workforce that will impact approximately 30% of its current employees, retaining approximately 23 employees essential to executing on t…”Filing
effective 31 peopleLayoffWARN noticeNewbury Park, CaliforniaNotice list
50% of workforceRestructuring planSEC 8-K“On March 3, 2025, the Company announced a reduction in its workforce that will impact approximately 50% of its current employees following the Company’s decision to discontinue all…”Filing
50% of workforceRestructuring planSEC 8-K“(the “Company”) announced a reduction in its workforce that will impact approximately 50% of its current employees.”Filing
25% of workforceRestructuring planSEC 8-K“(the “Company”) announced a reduction in its workforce that will impact approximately 25% of its current employees.”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Atara Biotherapeutics, Inc. compares in Biotechnology

  • Market cap$96 M · higher than 35% of 726
  • Revenue$121 M · higher than 71% of 647
  • Net margin27.1% · higher than 90% of 408
  • Revenue growth-6.3% · higher than 37% of 438
  • P/E ratio2.9× · lower than 92% of 100
  • Price / sales0.8× · lower than 96% of 339
  • FCF yield-53.0% · higher than 22% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Atara Biotherapeutics, Inc.🇺🇸$96 M2.9×27.1%-6.3%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 23, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on 2021
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, Wikidata, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Atara Biotherapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Atara Biotherapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Atara Biotherapeutics, Inc.? Suggest a correction